Epidemiological evidence on multiple system atrophy

Epidemiology of multiple system atrophy

✍ N. Vanacore; V. Bonifati; G. Fabbrini; C. Colosimo; G. De Michele; R. Marconi; D 📂 Article 📅 2001 🏛 Springer Milan 🌐 English ⚖ 39 KB

Differences between multiple system atro

Differences between multiple system atrophy and olivopontocerebellar atrophy

✍ Niall Quinn; Susan Daniel 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 3 views

Lynch and Sima [I] point out that glial cytoplasmic inclusions (GCIs

Multiple system atrophy: An update

✍ Gregor K. Wenning; Felix Geser; Michaela Stampfer-Kountchev; François Tison 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-d

Survival in multiple system atrophy

✍ Anette Schrag; Gregor K. Wenning; Niall Quinn; Yoav Ben-Shlomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract We here report survival in patients with multiple system atrophy (MSA) in a large, prospectively studied group of patients with MSA. Eighty‐five of 100 patients were known to have died. Three patients were rediagnosed as having PD. Twenty‐four patients came to autopsy, which showed MSA

Pain in multiple system atrophy

✍ F. Tison; G. K. Wenning; M. A. Volonte; W. R. Poewe; P. Henry; N. P. Quinn 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 388 KB

The diagnosis of multiple system atrophy

✍ Tommaso Caraceni 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 3 views